Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.21
$0.12
▼
$3.00
N/AN/A5,049 shs9 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+10.1%		$0.01
$0.00
▼
$0.23
N/AN/A65,007 shs300 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.09
+7.1%		$0.14
$0.05
▼
$0.81
N/AN/A2,386 shs250 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%+0.07%-11.76%-29.40%-90.62%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%-26.84%-15.76%-24.46%-57.62%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00%+8.67%-36.05%-71.43%-27.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.21
$0.12
▼
$3.00
N/AN/A5,049 shs9 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+10.1%		$0.01
$0.00
▼
$0.23
N/AN/A65,007 shs300 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.09
+7.1%		$0.14
$0.05
▼
$0.81
N/AN/A2,386 shs250 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%+0.07%-11.76%-29.40%-90.62%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%-26.84%-15.76%-24.46%-57.62%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00%+8.67%-36.05%-71.43%-27.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$559.42MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$5.61MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)

Latest ALVOW, APLMW, ARAV, and BIAFW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Alvotech stock logo
ALVOW
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
8/19/2026N/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
-$2.10N/AN/AN/A$1.70 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
10N/AN/ANot Optionable

Recent News About These Companies

BioAffinity and Pictor partner on diagnostics for asthma and COPD
July 24, 2026  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/bioaffinity-and-pictor-partner-on-diagnostics-for-asthma-and-copd/ar-AA28xCCa
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
July 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/bioaffinity-technologies-pictor-inc-partner-120800694.html
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
July 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/bioaffinity-technologies-quarterly-cypath-lung-124600075.html
WallachBeth Capital LLC: WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
June 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68812261-wallachbeth-capital-llc-wallachbeth-capital-announces-closing-of-bioaffinity-technologies-dollar-3-2-million-offering-008.htm
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for ...
June 16, 2026  |  lasvegassun.comL
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy ...
June 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/multidisciplinary-physician-panel-share-real-120000089.html
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
May 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/bioaffinity-technologies-announces-notification-mexico-120000631.html
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16
April 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/bioaffinity-technologies-cypath-lung-featured-120000290.html
bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
April 1, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/04/01/10357980.htm
BioAffinity Technologies stock cools off after strong Friday rally - here's why
March 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/bioaffinity-technologies-stock-cools-off-after-strong-friday-rally-here-s-why/ar-AA1YJQeR
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath(R) Lung
March 13, 2026  |  marketwatch.comhttps://www.marketwatch.com/press-release/bioaffinity-technologies-announces-record-2025-revenue-and-unit-sales-for-flagship-lung-cancer-diagnostic-cypath-r-lung-76fee528
BioAffinty Technologies, Brooke Army Medical Center Partner on Lung Cancer Test Study
February 26, 2026  |  360dx.com3
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung ...
February 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/bioaffinity-technologies-announces-validation-study-133000472.html
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
February 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/bioaffinity-technologies-appoints-nationally-recognized-130000121.html
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
January 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/bioaffinity-technologies-laboratory-maintains-prestigious-130000055.html
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 10.8% – Here’s What Happened
December 27, 2025  |  defenseworld.netD
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
December 3, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/bioaffinity-technologies-noninvasive-cypath-lung-130000149.html
Earnings roundup: Q3 rocky for bioAffinity and Spurs concessionaire
November 25, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/earnings-roundup-q3-rocky-for-bioaffinity-and-spurs-concessionaire/ar-AA1R2wFo
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
October 20, 2025  |  pharmiweb.comP
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
October 15, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/bioaffinity-technologies-regains-compliance-nasdaq-120000864.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)
As of 07/31/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.02 +0.00 (+10.07%)
As of 09:30 AM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 07/31/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAFW

$0.09 +0.01 (+7.09%)
As of 09:30 AM Eastern

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas